Our study examines how different imaging criteria can be used to assess brain tumor responses in patients with melanoma treated with immunotherapy drugs. We identified one imaging method that was more accurate in predicting survival compared to others. While further work is needed, our study is promising and highlights the importance of more consistent imaging standards in clinical trials.
Health Professionals
RELATIVITY-047: Extended Analysis Of Overall Survival With Nivolumab/Relatlimab vs Nivolumab In Previously Untreated Advanced Melanoma
In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma.
Melanoma tumors thicker than 0.8 mm increase risk for death
The crude incidence rate of melanoma-related death 20 years after diagnosis was 6% for those with tumors thinner than 0.8 mm.
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.